We review antifungal susceptibility testing and the development of clinical breakpoints, and detail an approach to using antifungal susceptibility results when breakpoints have not been defined. This information may prove helpful when selecting therapy for invasive fungal infections in children.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305799 | PMC |
http://dx.doi.org/10.1093/jpids/piad014 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!